Basicmedical Key

Fig. 3.1 A Jabloński diagram depicting fluorophore absorption, radiative, and non-radiative ­relaxation pathways. Singlet ground, first, and second electronic states are represented by S 0, S 1, and S 2….

Fig. 8.1 Schematic of overall protein stability The choice of which biophysical methods to use is dictated by the types of studies and specific requirements that support protein drug development….

Fig. 7.1 Far-UV (a) and near-UV (b) CD spectra of pilot-scale and full-scale drug substance lots in clinical and commercial formulations, respectively. Lots 1 and 2 are pilot-scale lots; Lots…

Fig. 9.1 Analytical characterization of IgG1 monoclonal antibody solutions containing soluble aggregates measured by orthogonal methods, SE-HPLC (a, b, c) and SV-AUC (d, e, f). Protein aggregates of varying size…

Fig. 5.1 (a) Far-UV CD spectra of protein 1–4 (spectral similarity compared to that of protein 1 is 100% protein 1; 5.0% protein 2; 44.9% protein 3; 28.7% protein 4)….

Fig. 2.1 Representative differential scanning fluorometry spectra obtained with a therapeutic protein on 96-well plate filled with different formulations for each well. Fluorescence intensity in relative fluorescence units (RFU) is…

Fig. 10.1 Microparticle analysis procedure The majority of the microparticles can be isolated through filtration using filter appropriate for the planned analysis. A gold-coated membrane filter (Rapid-ID, Berlin, Germany) facilitates…

Instabilities 1. Physical • Conformational stability  Thermal denaturation  Cold denaturation  Pressure-induced denaturation  Chemical denaturation • Colloidal stability • Surface/interfacial-induced denaturation 2. Chemical • Deamidation • Asp isomerization • Fragmentation •…